• In early January 2026, MUSC Health announced a multi-year partnership with Baxter International to improve patient care using integrated connected care technologies, aiming to streamline bedside workflows, enhance quality and safety, and boost nurse satisfaction through advanced data and automation tools.
• This collaboration positions Baxter as a key partner in shaping future nursing workflows and connected hospital infrastructure, potentially making its digital and automation capabilities more influential across the wider healthcare system.
• Next, we’ll examine how this focus on connected nursing workflows and real-time data integration may influence Baxter’s existing investment narrative.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Baxter International Investment Narrative Recap

To own Baxter today, you need to believe it can turn operational improvements, portfolio pruning and connected-care innovation into steadier profitability despite recent losses and margin pressure. The MUSC Health partnership reinforces Baxter’s push into higher-value, data-enabled infusion and monitoring solutions, but it does not materially change the near term focus on margin repair or the key risk around IV fluid demand and product mix.

The MUSC collaboration best ties into Baxter’s catalyst around innovation in advanced infusion systems and connected, data-rich devices. It showcases how the company’s digital and automation tools might be embedded into real-world nursing workflows, which investors already watch as a potential source of higher-margin growth. It also sets the stage for management to highlight progress at events like the J.P. Morgan Healthcare Conference in San Francisco.

However, investors should also be aware that even as connected-care partnerships gain attention, Baxter still faces ongoing quality and regulatory risk around its Novum IQ infusion pumps, which...

Baxter International's narrative projects $12.1 billion revenue and $913.6 million earnings by 2028. This requires 3.7% yearly revenue growth and a $1,160.6 million earnings increase from -$247.0 million.

Uncover how Baxter International's forecasts yield a $23.80 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Seven fair value estimates from the Simply Wall St Community range from about US$14.80 to an extreme outlier above US$20,000, showing just how far opinions can stretch. Against that backdrop, Baxter’s push into connected, AI enabled infusion and monitoring systems through partnerships like MUSC Health could be a key factor you weigh when comparing these very different views on its future performance.

Explore 7 other fair value estimates on Baxter International - why the stock might be a potential multi-bagger!

Build Your Own Baxter International Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Baxter International research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Baxter International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Baxter International's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Outshine the giants: these 28 early-stage AI stocks could fund your retirement.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.